
    
      The hypothesis of this study is in Ulcerative Colitis (UC) patients with tissue
      CytoMegaloVirus (CMV) reactivation ; not responding to anti-TNF or without anti-TNF ; a
      treatment with valganciclovir, added to vedolizumab, could improve the clinical response.
    
  